Combination therapies
View Patent ↗Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
1. A method of treating breast cancer, comprising administering to a subject in need thereof an effective amount of
(i) an angiogenesis inhibitor that is nintedanib, dovitinib, regorafenib, or bevacizumab; and
(ii) 3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol (compound 5).
2. The method of claim 1 , wherein the angiogenesis inhibitor is nintedanib, dovitinib, or regorafenib.
3. The method of claim 1 , wherein the angiogenesis inhibitor is bevacizumab.
4. The method of claim 1 , wherein the breast cancer is refractory, non-responsive, or resistant to chemotherapy and/or haploidentical stem cell transplantation.
5. The method of claim 4 , wherein the breast cancer is non-responsive or resistant to the angiogenesis inhibitor.
6. The method of claim 1 , wherein the angiogenesis inhibitor and 3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol (compound 5) are administered simultaneously or sequentially.